迎接挑战:掌握克洛斯特里迪奥伊德困难感染的管理
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Mayo Clinic proceedings
|June 5, 2024
概括
困难菌感染 (CDI) 是一个越来越令人担忧的问题,社区获得的病例越来越多. 本综述涵盖了CDI的最新诊断和管理策略,包括微生物组恢复疗法.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 困难菌感染 (CDI) 是一个重大的公共卫生挑战,在传统医疗机构之外的社区中越来越多地出现.
- 越来越多的社区获得的CDI病例发生在没有典型风险因素的个体中,例如之前使用抗生素.
- 肠道微生物失调是驱动CDI的潜在病理生理过程.
研究的目的:
- 为临床医生提供关于CDI当前诊断方法的简短综述.
- 为原发性和复发性Clostridioides difficile感染概述当代的管理策略.
- 突出CDI治疗的最新进展,包括新型抗生素和微生物组恢复.
主要方法:
- 文献综述,重点关注最近CDI诊断和治疗方面的进展.
- 综合有关新兴诊断工具和治疗方案的信息.
- 讨论微生物群恢复策略,包括便微生物群移植和活生物疗法.
主要成果:
- 对于CDI的诊断景观已经随着新的测试方式而发展.
- 新型抗生素治疗为管理CDI提供了替代选择.
- 微生物群的恢复,包括便微生物群移植和批准的活生物疗法,是重要的治疗策略.
结论:
- 由于CDI对公共健康的影响,有效的诊断和管理是至关重要的.
- 更新的治疗指南包括新型抗生素和基于微生物组的疗法.
- 临床医生需要了解Clostridioides difficile感染的流行病学和管理的变化.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:24Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154
01:21Inflammatory Bowel Disease V: Surgical Management
139
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
139
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
195
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
195
01:21Drugs for Treatment of Constipation-Predominant IBS
157
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
157